Doxazosin in patients with hypertension
- 31 Downloads
The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients.
For an 8 mg daily dose mean Cmax at steady-state for all patients was 108 ng/ml; the mean tmax was 1.8 h. The mean terminal elimination half-life was 22 h. The four tablets containing 1, 2, 4, or 8 mg of doxazosin were bioequivalent in delivering the 8 mg dose.
In patients with mild to moderate hypertension, 26-day treatment with doxazosin resulted in blood pressure reduction of 10/7 mm Hg in the supine and 13/18 mm Hg in the standing position. Adverse effects were generally mild and of brief duration.
Key wordsdoxazosin hypertension alpha-adrenergic blockade bioavailability pharmacokinetics adverse effects
Unable to display preview. Download preview PDF.
- 1.Cubeddu LX, Fuenmayor N, Caplan N, Ferry D (1987) Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther 41: 439–449Google Scholar
- 2.Elliot HL, Meredith PA, Sumner DJ, McLean K, Reid JL (1982) A pharmacodynamic and pharmacokinetic assessment of a new α-adrenoceptor antagonist, doxazosin (UK 33274) in normotensive subjects. Br J Clin Pharmacol 13: 699–703Google Scholar
- 3.Vincent J, Elliot HL, Meredith PA, Reid JL (1983) Doxazosin, an α-adrenoceptor antagonist: Pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol 15: 719–725Google Scholar